Kaken Pharmaceutical Company, Ltd
http://www.kaken.co.jp/english/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kaken Pharmaceutical Company, Ltd
Finance Watch: Vicebio Adds To 2024’s Mega-Round Total With $100m Series B
Private Company Edition: Vicebio plans to take a combo vaccine into Phase I with its $100m series B venture capital round. Also, Nura Bio raised $68m to boost its series A total to $141m and George Church-founded GC Therapeutics launched with $75m, among other recent VC deals.
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer
Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
J&J Continues Atopic Dermatitis Effort With Numab Deal
Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Kaken Pharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice